Executive Summary
Redo SAVR after a failed TAVR carries operative mortality of 12-17% versus 1-9% after a failed surgical valve — a gap that should reframe how heart teams counsel 65-to-75-year-olds about a "TAVR-first" lifetime plan. A narrative review in Journal of Clinical Medicine pulls together four datasets totaling 35,677 patients and finds the excess mortality persists after propensity matching and across all risk strata, including low-risk patients (observed-to-expected ratio up to 5.48). A Circulation sub-analysis of NOTION-3 addresses angina-driven outcomes after PCI in TAVI patients, and a meta-analysis in Heart Rhythm O2 ties conduction system pacing post-TAVR to lower HF rehospitalization. The week's signal: durability and reintervention math tighten the case for SAVR in operable patients under 70, exactly where ESC 2025 already drew the line.
- Redo SAVR after TAVR: 12-17% operative mortality vs 1-9% after prior SAVR, persisting across all risk strata (PMID 42194605).
- Portico vs SAPIEN 3 meta-analysis (20,522 patients) shows higher moderate-to-severe paravalvular leak, more pacemakers, and higher 1-year mortality with Portico (PMID 42194547).
- Conduction system pacing after TAVR reduces HF rehospitalization vs RV pacing in 800-patient meta-analysis (Heart Rhythm O2).
- TRI-SCORE-stratified analysis of 361 T-TEER patients: residual SYNTAX score predicts mortality only in low/intermediate-risk CAD subgroups (PMID 42191313).
- FDA Class I recall hits a vascular access device used in TAVR and peripheral cases (Cardiovascular Business).
What to watch: Medtronic Q4 earnings drop June 3, the first read on Structural Heart's Evolut and Intrepid momentum since the DEDICATE follow-up data started reshaping competitive positioning against Edwards.
Aortic Valve (TAVR/TAVI)
The TAVR-explant problem is now a number we can quote at heart team meetings. [NOTABLE] A narrative review of four studies and 35,677 patients pegs operative mortality of redo SAVR after TAVR at 12-17% versus 1.1-9% after prior SAVR, with propensity-matched odds ratios as high as 12.5 and observed-to-expected ratios exceeding 1.0 even in low-risk patients. TAVR-SAVR volume is growing at up to 144.6% annually and may eclipse SAVR-SAVR by 2029. Shorter bypass times despite worse outcomes point to cumulative organ injury, not surgical complexity, as the driver. ESC 2025 already prefers SAVR below age 70 on exactly these grounds; ACC/AHA 2020 calls for shared decision-making from age 65-80 but has not yet incorporated explant-era mortality data.
The device side echoes the durability concern. A meta-analysis of 20,522 patients comparing Abbott's Portico vs SAPIEN 3 found Portico associated with 3.27-fold higher moderate-to-severe PVL, 62% more pacemakers, and 26% higher 1-year mortality (RR 1.26, p=0.01). The analysis is observational, so unmeasured confounding cannot be excluded, but the signal aligns with prior self-expanding vs balloon-expandable comparisons. A separate observational meta-analysis in 5,365 reduced-EF patients found self-expanding valves yielded better LVEF recovery but 2.5x more moderate-or-worse PVL versus balloon-expandable — no mortality difference at available follow-up.
On conduction: an 800-patient meta-analysis in Heart Rhythm O2 reports conduction system pacing post-TAVR delivers higher LVEF and fewer HF rehospitalizations vs RV pacing — directly relevant given pacemaker rates remain high with self-expanding platforms.
Mitral Valve (MitraClip, PASCAL, TMVR)
A cross-platform technical report from Cardiovascular Intervention and Therapeutics describes using the TriClip steerable guide catheter to deliver MitraClip — bench-tested and applied in a single case. Operators dealing with challenging mitral anatomy may borrow tricuspid hardware to improve reach. This is a workflow signal, not a guideline-grade finding.
A single-center retrospective study of 106 TEER patients found baseline ALBI score (albumin-bilirubin) independently predicted long-term mortality (HR 3.35, AUC 0.877), modestly improving discrimination over standard models. Useful for risk discussions, but the retrospective single-center design limits generalizability and doesn't change patient selection. COAPT-criteria patients still belong in the cath lab per ESC 2025 (Class I) and ACC/AHA 2020 (Class IIa). For symptomatic severe primary MR, both guidelines recommend surgical repair (Class I) as first line, with TEER reserved for prohibitive surgical risk; for ventricular SMR, COAPT/RESHAPE-HF2/Tri.Fr has shifted Europe to Class I for TEER while ACC/AHA holds at IIa.
Tricuspid Valve (TriClip, TTVR)
A 361-patient cohort in JACC: Cardiovascular Interventions showed obstructive CAD is present in 34% of T-TEER patients but is low-complexity (median SYNTAX 6). Residual SYNTAX score after revascularization independently predicted mortality only in low- and intermediate-risk patients per TRI-SCORE; in high-risk patients, advanced TR substrate dominated outcomes. The practical read: don't over-revascularize sick T-TEER candidates, but do consider PCI in earlier-stage patients before TEER.
A separate systematic review of 59 studies confirmed residual TR ≥3+ post T-TEER doubles mortality risk (HR 2.19) and is the most consistent predictor across endpoints. Two further multicenter reports — the TITAN Registry of Cardioband annuloplasty and a multicenter annuloplasty-then-TEER series — broaden the transcatheter toolkit for TR. ESC 2025 elevated TV surgery for symptomatic primary TR to Class I and for asymptomatic severe primary TR with RV dilation to IIa; ACC/AHA 2020 sits at IIa and IIb respectively. Transcatheter TV intervention is ESC IIa LOE A (2025), absent from ACC/AHA 2020. Across both guideline traditions, the consistent finding is late referral — patients arrive with established RV dysfunction, narrowing the window for any intervention.
Surgical vs. Transcatheter Comparisons
Two findings sharpen the surgical case in younger patients this week. First, the TAVR-explant mortality data above. Second, an analysis of patients aged 50-70 found mechanical aortic prostheses outperformed bioprostheses for long-term survival, with 19-mm bioprostheses showing the worst outcomes and severe PPM driving lowest survival. The Cedars-Sinai NCT07605715 randomized trial of transcatheter vs surgical degenerative MR repair just began recruiting (N=60) — small, but a symbolically important head-to-head in primary MR where surgery currently dominates both guidelines.
The narrative arc: every transcatheter advance carries a downstream reintervention cost when applied to patients with 15+ years of life expectancy. ACC/AHA's age-65 SAVR threshold and ESC's age-70 SAVR threshold look increasingly defensible against this week's data.
Device & Technology
Narayana Health City reported India's first TAVI with the Hanchor valve for pure aortic regurgitation. TAVI for AR remains a niche indication: ESC 2025 lists it as Class IIb in inoperable patients with suitable anatomy; ACC/AHA 2020 does not endorse it. A JACC: CV Interventions case report reminds operators that leaflet perforation during TAVI for pure AR hinges on annulo-aortic angulation — anatomy-dependent and not yet a routine procedure.
Regulatory & Policy
The FDA confirmed a Class I recall on a vascular device used in TAVR and peripheral procedures. Class I is the most serious tier — reasonable probability of serious injury or death. Operators should check current access kits.
Financial Analysis
Edwards' clean run continues, with EW tagging a fresh 52-week high at $87.89 on the back of structural-heart consensus that the company's TAVR, PASCAL, and EVOQUE franchises sit at the center of every guideline expansion this cycle. The absolute YTD performance — up only 1% over six months — masks how much air has come out of the broader medtech complex. Boston Scientific (-43% over six months) and Abbott (-32%) reflect sector-wide repricing despite both companies delivering raised guidance and structural-heart growth. Boston Scientific is leaning hard on WATCHMAN to backstop structural heart momentum. Medtronic faces a make-or-break Q4 print June 3 with its Evolut and Intrepid franchises under scrutiny after the TAVR-explant durability data started landing.
The clinical evidence and the tape are diverging. Operators are reading durability data that cools enthusiasm for TAVR in younger patients; the market is pricing structural heart as if penetration only goes up. The reconciliation comes in the next 18 months.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $87.54, +2.05% on the day, +1.00% over 6 months
- Market cap: $50.4B | P/E (trailing): 47.32 | P/E (forward): 26.02 | Beta: 0.87
- 52-week range: $72.30-$87.93 (closed at the high)
- Analyst target: $97.15 (27 analysts, Buy)
- Next earnings: July 23, EPS est $0.74, revenue est $1.70B
- Commentary: EW broke through to a new 52-week high. Institutional flows mixed — L&G holds $376M, while Jefferies trimmed its position. PASCAL and EVOQUE drive optionality.
Medtronic (MDT)
- Price: $77.60, -1.27% on the day, -25.18% over 6 months
- Market cap: $99.6B | P/E (trailing): 21.68 | P/E (forward): 12.81 | Beta: 0.63
- 52-week range: $74.40-$106.33
- Analyst target: $107.08 (26 analysts, Buy)
- Next earnings: June 3, EPS est $1.55, revenue est $9.61B
- Commentary: Trading near 52-week lows ahead of next week's print. Investors want Evolut growth detail and management's response to TAVR-SAVR durability/explant data. Intrepid TMVR Pivotal continues enrolling.
Abbott (ABT)
- Price: $86.67, -0.85% on the day, -32.00% over 6 months
- Market cap: $151.0B | P/E (trailing): 24.28 | P/E (forward): 14.29 | Beta: 0.65
- 52-week range: $81.97-$139.06
- Analyst target: $118.64 (25 analysts, Buy)
- Next earnings: July 16, EPS est $1.28, revenue est $12.53B
- Commentary: The Portico meta-analysis signal is the headwind to watch — higher PVL, pacemakers, and 1-year mortality vs SAPIEN 3 in 20,522 patients. MitraClip and TriClip remain the franchise anchors; REPAIR-MR readout still pending.
Boston Scientific (BSX)
- Price: $57.64, -0.24% on the day, -43.26% over 6 months
- Market cap: $85.7B | P/E (trailing): 24.12 | P/E (forward): 15.32 | Beta: 0.62
- 52-week range: $52.52-$109.50
- Analyst target: $83.47 (32 analysts, Strong Buy)
- Next earnings: July 29, EPS est $0.83, revenue est $5.40B
- Commentary: Worst structural heart performer over 6 months despite strong fundamentals and raised guidance. WATCHMAN remains the LAAO growth story; ACURATE neo2 international momentum continues, US runway depends on label evolution.
Anteris Technologies (AVR.AX)
- Price: AU$12.66, -4.45% on the day, +109.26% over 6 months
- Market cap: AU$1.2B | P/E (forward): -5.81 | Beta: 0.59
- 52-week range: AU$4.68-$13.80
- Commentary: The DurAVR THV story has driven a double in six months — speculative, but reflects investor appetite for a novel single-piece bovine pericardial design as durability concerns reshape the TAVR conversation.
Market outlook: The structural heart trade has bifurcated. EW and AVR.AX trade on bull-case durability and pipeline expansion stories; MDT, ABT, and BSX absorb sector-wide medtech multiple compression. The next 12 months — Medtronic's print, NOTION-3 follow-ups, EARLY TAVR durability tails, and the first TAVR-explant registries with matched controls — will determine whether the bifurcation persists or reconverges.
Clinical Trial Updates
Aortic:
- NCT06830499 — SAPIEN 3 TAVR in Young Chinese AS Patients | Recruiting | N=450 | Xijing Hospital. Important geographic and demographic dataset for an under-studied population.
- NCT07605780 — TAVI in Low Risk Real World | Completed | N=650 | Centro Cardiologico Monzino. Readout pending; real-world low-risk durability data will sit alongside DEDICATE.
- NCT07193888 — Navitor Japan Study | Recruiting | N=100 | Abbott. Regional expansion data for Abbott's next-gen valve.
- NCT07604402 — TAVI Without On-Site Cardiac Surgery | Not Yet Recruiting | N=1,612 | University Hospital of Ferrara. A direct test of the regulatory question that has divided ACC/AHA (requires on-site surgery) from European centers.
- NCT02701283 — [LANDMARK] Evolut Low Risk Long-Term Follow-Up | Active Not Recruiting | N=2,223 | Medtronic. Multi-year durability readouts feed directly into the guideline debate.
- NCT06171802 — EMPagliflozin After AVR | Completed | N=206 | Rigshospitalet. SGLT2-inhibitor adjunctive therapy after AVR — phase 4 readout pending.
Mitral Repair:
- NCT04198870 — [LANDMARK] REPAIR-MR (MitraClip vs surgery for primary MR) | Active Not Recruiting | N=500 | Abbott. The most consequential transcatheter-vs-surgical head-to-head in primary MR.
- NCT05051033 — [LANDMARK] PRIMATY (TEER vs medical therapy for secondary MR) | Recruiting | N=450 | Annetine Gelijns.
- NCT03706833 — [LANDMARK] COAPT Long-Term Follow-Up | Active Not Recruiting | N=1,247 | Edwards. 5-year readouts already underpin ESC's Class I upgrade.
- NCT04147884 — Millipede Annuloplasty Feasibility | Active Not Recruiting | N=4 | Boston Scientific.
- NCT07605715 — Transcatheter vs Surgical Degenerative MR | Recruiting | N=60 | Cedars-Sinai. Small but symbolically important.
Mitral Replacement:
- NCT03242642 — [LANDMARK] Intrepid TMVR Pivotal | Recruiting | N=1,056 | Medtronic.
- NCT06414265 — SATURN Trans-Septal TMVR | Recruiting | N=30 | InnovHeart.
Tricuspid Repair:
- NCT03904147 — [LANDMARK] TRILUMINATE Pivotal (TriClip) | Active Not Recruiting | N=572 | Abbott. Underpins ESC's Class IIa transcatheter TR endorsement.
- NCT04097145 — [LANDMARK] CLASP II TR (PASCAL) | Recruiting | N=1,270 | Edwards.
Tricuspid Replacement:
- NCT04482062 — [LANDMARK] TRISCEND II (EVOQUE) | Active Not Recruiting | N=864 | Edwards.
- NCT06458907 — TricValve Bicaval Pivotal | Not Yet Recruiting | N=780 | P+F Products. A bicaval rather than orthotopic approach — distinct competitive lane.
Next week's calendar pivots on Medtronic's June 3 print, where Evolut volume commentary will be parsed against this week's TAVR-explant data and the Portico meta-analysis. If management addresses durability and lifetime management head-on, structural heart sentiment may stabilize. If not, the gap between guideline trajectory and market positioning gets wider.